Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial

• Published in: JAMA : the journal of the American Medical Association Vol. 281; no. 3; pp. 235 - 242
• Main Authors: Davidson, Michael H, Hauptman, Jonathan, DiGirolamo, Mario, Foreyt, John P, Halsted, Charles H, Heber, David, Heimburger, Douglas C, Lucas, Charles P, Robbins, David C, Chung, Jain, Heymsfield, Steven B
• Format: Journal Article
• Language: English
• Published: Chicago, IL American Medical Association 20.01.1999
• Subjects: Adult; Analysis of Variance; Biological and medical sciences; Blood Glucose; Blood Pressure; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Double-Blind Method; Drug therapy; Energy Intake; Enzyme Inhibitors - therapeutic use; Female; Follow-Up Studies; General and cellular metabolism. Vitamins; Health risk assessment; Humans; Insulin - blood; Lactones - therapeutic use; Lipase - antagonists & inhibitors; Lipids - blood; Male; Medical sciences; Obesity; Obesity - complications; Obesity - diet therapy; Obesity - drug therapy; Obesity - metabolism; Orlistat; Pharmacology. Drug treatments; Risk Factors; Weight control; Weight Loss; United States; North America; America; Human; Evaluation; Obesity; Nutrition disorder; Weight loss; Metabolic diseases; Controlled therapeutic trial; Prevention; Chemical reduction; Randomization; Association; Diet therapy; Risk factor; Orlistat; Public health; Nutritional status; Antilipemic agent

CONTEXT Orlistat, a gastrointestinal lipase inhibitor that reduces dietary fat absorption by approximately 30%, may promote weight loss and reduce cardiovascular risk factors. OBJECTIVE To test the hypothesis that orlistat combined with dietary intervention is more effective than placebo plus diet f...